Information Provided By: 
Fly News Breaks for June 8, 2017
INO
Jun 8, 2017 | 11:04 EDT
Piper Jaffray analyst Charles Duncan upgraded Inovio Pharmaceuticals to Overweight from Neutral and raised his price target for the shares to $14 from $9. The lifting of the clinical hold and Phase III trial start of VGX-3100 reduces risk, Duncan tells investors in a research note. The analyst now has confidence that Inovio's early-stage efforts can eventually move into later-stage.
News For INO From the Last 2 Days
There are no results for your query INO
